Fennell D, Griffiths D, Eminton Z, Morgan-Fox A, Hill K, Ewings S
BMJ Open. 2023; 13(11):e073120.
PMID: 37993149
PMC: 10668324.
DOI: 10.1136/bmjopen-2023-073120.
Marley-Zagar E, White I, Royston P, Barthel F, Parmar M, Babiker A
Stata J. 2023; 23(1):24-52.
PMID: 37461744
PMC: 7614770.
DOI: 10.1177/1536867X231161971.
White I, Marley-Zagar E, Morris T, Parmar M, Royston P, Babiker A
Stata J. 2023; 23(1):3-23.
PMID: 37155554
PMC: 7614472.
DOI: 10.1177/1536867X231161934.
Pathak S, Lai F, Miksza J, Petrie M, Roman M, Murray S
Eur Heart J. 2022; 44(5):351-364.
PMID: 36350978
PMC: 9890210.
DOI: 10.1093/eurheartj/ehac670.
Jachno K, Heritier S, Wolfe R
BMC Med Res Methodol. 2021; 21(1):177.
PMID: 34454428
PMC: 8399795.
DOI: 10.1186/s12874-021-01372-0.
Protocol for a randomised controlled trial for Treatment in Thoracic Aortic Aneurysm: Surgery versus Surveillance (TITAN: SvS).
Guo M, Appoo J, Wells G, Chu M, Ouzounian M, Fortier J
BMJ Open. 2021; 11(5):e052070.
PMID: 34039580
PMC: 8160193.
DOI: 10.1136/bmjopen-2021-052070.
Increasing the power of randomized trials comparing different treatment durations.
Ouyang Y, Qian H, Yatham L, Wong H
Contemp Clin Trials Commun. 2020; 19:100588.
PMID: 32617431
PMC: 7322686.
DOI: 10.1016/j.conctc.2020.100588.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A
BMC Cancer. 2019; 19(1):504.
PMID: 31138244
PMC: 6537200.
DOI: 10.1186/s12885-019-5600-x.
Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K, Heritier S, Wolfe R
BMC Med Res Methodol. 2019; 19(1):103.
PMID: 31096924
PMC: 6524252.
DOI: 10.1186/s12874-019-0749-1.
The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression.
Okereke O, Reynolds 3rd C, Mischoulon D, Chang G, Cook N, Copeland T
Contemp Clin Trials. 2018; 68:133-145.
PMID: 29526608
PMC: 5899680.
DOI: 10.1016/j.cct.2018.02.017.
The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP.
Streckmann F, Balke M, Lehmann H, Rustler V, Koliamitra C, Elter T
BMC Cancer. 2018; 18(1):62.
PMID: 29316888
PMC: 5761113.
DOI: 10.1186/s12885-017-3866-4.
Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.
Yang Q, Fung W, Li G
Stat Med. 2017; 37(8):1389-1401.
PMID: 29282764
PMC: 6148356.
DOI: 10.1002/sim.7590.
Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.
Wu J, Xiong X
Stat Biopharm Res. 2017; 9(1):35-43.
PMID: 28966722
PMC: 5619877.
DOI: 10.1080/19466315.2016.1189355.
Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model.
Wu J
Stat Biopharm Res. 2017; 9(1):25-34.
PMID: 28966721
PMC: 5619878.
DOI: 10.1080/19466315.2016.1174147.
A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.
Xia F, George S, Wang X
Stat Biopharm Res. 2016; 8(1):12-21.
PMID: 27239255
PMC: 4879617.
DOI: 10.1080/19466315.2015.1093539.
Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P, Parmar M
BMC Med Res Methodol. 2016; 16:16.
PMID: 26869168
PMC: 4751641.
DOI: 10.1186/s12874-016-0110-x.
miR-520h is crucial for DAPK2 regulation and breast cancer progression.
Su C, Wang M, Hong C, Chen H, Su Y, Wu C
Oncogene. 2015; 35(9):1134-42.
PMID: 25982274
DOI: 10.1038/onc.2015.168.
An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P, Parmar M
Trials. 2014; 15:314.
PMID: 25098243
PMC: 4133607.
DOI: 10.1186/1745-6215-15-314.
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
Royston P, Parmar M
BMC Med Res Methodol. 2013; 13:152.
PMID: 24314264
PMC: 3922847.
DOI: 10.1186/1471-2288-13-152.
A double-blind block randomized clinical trial on the effect of zinc as a treatment for diarrhea in neonatal Holstein calves under natural challenge conditions.
Glover A, Puschner B, Rossow H, Lehenbauer T, Champagne J, Blanchard P
Prev Vet Med. 2013; 112(3-4):338-47.
PMID: 24074841
PMC: 7114245.
DOI: 10.1016/j.prevetmed.2013.09.001.